Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator.

[1]  R. Tracy,et al.  Intracerebral hemorrhage related to cerebral amyloid angiopathy and T‐PA treatment , 1991, Annals of neurology.

[2]  J. Gore,et al.  Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. , 1991, Circulation.

[3]  M. Sloan,et al.  The syndrome of bilateral hemispheric border zone ischemia. , 1990, Stroke.

[4]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.

[5]  D. Collen.  Coronary thrombolysis: streptokinase or recombinant tissue-type plasminogen activator? , 1990, Annals of internal medicine.

[6]  J. Gore,et al.  Intracranial hemorrhage after rt-pa and heparin for acute myocardial infarction — The TIMI II pilot and randomized trial combined experience , 1990 .

[7]  C. Hamm,et al.  In vitro effects of thrombolytic agents on platelets , 1990 .

[8]  R. Califf,et al.  Intracranial hemorrhage after thrombolytic therapy for acute myocardial infarction: Clinical characteristics and in-hospital outcome , 1990 .

[9]  B. Coller.  Platelets and thrombolytic therapy. , 1990, The New England journal of medicine.

[10]  G. Weismer.  Orofacial impairment in Parkinson's disease , 1990, Neurology.

[11]  C. Kase,et al.  Intracranial hemorrhage after use of tissue plasminogen activator for coronary thrombolysis. , 1990, Annals of internal medicine.

[12]  H. Gold,et al.  Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. , 1989, Circulation.

[13]  R. Kelley,et al.  Effect of residue 65 substitutions on thermal stability of tissue plasminogen activator kringle-2 domain. , 1989, Biochemistry.

[14]  E. Topol,et al.  Thrombolytic therapy for acute myocardial infarction. , 1989, Chest.

[15]  J. Tintinalli,et al.  Associated reactions during and immediately after rtPA infusion. , 1989, Annals of emergency medicine.

[16]  R. Califf,et al.  Hemorrhagic complications of thrombolytic therapy in the treatment of myocardial infarction and venous thromboembolism. , 1989, Chest.

[17]  F. Van de Werf,et al.  Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. , 1988, BMJ.

[18]  E. Braunwald,et al.  Tissue plasminogen activator. , 1988, The New England journal of medicine.

[19]  E. Topol,et al.  Intracerebral hemorrhage complicating intravenous tissue plasminogen activator treatment. , 1988, Archives of neurology.

[20]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[21]  R. Califf,et al.  Hemorrhagic complications associated with the use of intravenous tissue plasminogen activator in treatment of acute myocardial infarction. , 1988, The American journal of medicine.

[22]  P. Thompson.  CORONARY THROMBOLYSIS AND MYOCARDIAL SALVAGE BY TISSUE PLASMINOGEN ACTIVATOR , 1988, The Lancet.

[23]  Dwight E. Peake,et al.  Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase , 1988 .

[24]  Sol Sherry,et al.  Thrombolytic Therapy: Current Status , 1988 .

[25]  M. O'Rourke,et al.  Limitation of myocardial infarction by early infusion of recombinant tissue-type plasminogen activator. , 1988, Circulation.

[26]  R. Califf,et al.  Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarction. , 1988, The American journal of cardiology.

[27]  H. Lambertz,et al.  THROMBOLYSIS WITH TISSUE PLASMINOGEN ACTIVATOR IN ACUTE MYOCARDIAL INFARCTION: NO ADDITIONAL BENEFIT FROM IMMEDIATE PERCUTANEOUS CORONARY ANGIOPLASTY , 1988, The Lancet.

[28]  A. Jaffe,et al.  Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .

[29]  E. Topol,et al.  A randomized trial of intravenous tissue plasminogen activator for acute myocardial infarction with subsequent randomization to elective coronary angioplasty. , 1987, The New England journal of medicine.

[30]  B. Chaitman,et al.  The Thrombolysis in Myocardial Infarction (TIMI) phase II pilot study: tissue plasminogen activator followed by percutaneous transluminal coronary angioplasty. , 1987, Journal of the American College of Cardiology.

[31]  K. Lee,et al.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.

[32]  S. Forman,et al.  Thrombolysis in myocardial infarction (TIMI): comparative studies of coronary reperfusion and systemic fibrinogenolysis with two forms of recombinant tissue-type plasminogen activator. , 1987, Journal of the American College of Cardiology.

[33]  R Roberts,et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. , 1987, Circulation.

[34]  E. Topol,et al.  A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction. , 1987, Journal of the American College of Cardiology.

[35]  H. Vinters.  Cerebral amyloid angiopathy. A critical review. , 1987, Stroke.

[36]  Harold T. Dodge,et al.  Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase* , 1987 .

[37]  C. Kase.  Intracerebral hemorrhage: non-hypertensive causes. , 1986, Stroke.

[38]  D. Collen,et al.  Thrombolytic therapy in the eighties. , 1986, Blood.

[39]  E. Topol,et al.  Coronary thrombolysis with recombinant tissue-type plasminogen activator. A hematologic and pharmacologic study. , 1985, Annals of internal medicine.

[40]  R. W. Brower,et al.  DOUBLE-BLIND RANDOMISED TRIAL OF INTRAVENOUS TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS PLACEBO IN ACUTE MYOCARDIAL INFARCTION , 1985, The Lancet.

[41]  R. W. Brower,et al.  RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.

[42]  A. Schafer,et al.  Plasmin inhibition of platelet function and of arachidonic acid metabolism. , 1985, The Journal of clinical investigation.

[43]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[44]  B E Sobel,et al.  Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. , 1984, Circulation.

[45]  R. Califf,et al.  Myocardial infarction and stroke , 1984, Neurology.

[46]  J. Burke,et al.  Left ventricular mural thrombi complicating acute myocardial infarction. Long-term follow-up with serial echocardiography. , 1984, Annals of internal medicine.

[47]  H. Vinters,et al.  Cerebral amyloid angiopathy: incidence and complications in the aging brain. I. Cerebral hemorrhage. , 1983, Stroke.

[48]  H. Vinters,et al.  Cerebral amyloid angiopathy: incidence and complications in the aging brain. II. The distribution of amyloid vascular changes. , 1983, Stroke.

[49]  M. Kupersmith,et al.  Intracranial Hemorrhage and Infarction in Anticoagulated Patients with Prosthetic Heart Valves , 1978, Stroke.

[50]  R. Gabriel.  IgA DEFICIENCY, HYPERTENSION, AND MULTICYSTIC RENAL DISEASE , 1976, The Lancet.

[51]  B. Kadis.  Letter: Lithium and magnesium-dependent enzymes. , 1974, Lancet.

[52]  R. Ebert,et al.  Anticoagulants in acute myocardial infarction: results of a cooperative clinical trial , 1973 .

[53]  S. Niewiarowski,et al.  Plasmin-induced platelet aggregation and platelet release reaction. Effects on hemostasis. , 1973, The Journal of clinical investigation.

[54]  A Drapkin,et al.  Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction. , 1972, JAMA.

[55]  A. Handley,et al.  Heparin in the Prevention of Deep Vein Thrombosis after Myocardial Infarction , 1972, British medical journal.

[56]  L. Gutterman,et al.  Anticoagulants in acute myocardial infarction. The failure of anticoagulants to alter mortality in a randomized series. , 1966, American heart journal.

[57]  Barr Jb,et al.  HOME OR AWAY? , 1964, Lancet.

[58]  M. Verstraete,et al.  A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). , 1963, Clinica chimica acta; international journal of clinical chemistry.

[59]  C. Sanders,et al.  Heparin administration after acute myocardial infarction. , 1960, The New England journal of medicine.